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The unexpected announcement of Symplicity HTN-3 trial by the sponsor company 
that renal sympathetic denervation (RDN) failed to meet its primary efficacy end-point 
at 6 months raised concerns regarding the extent of blood pressure (BP) lowering 
results of the procedure.1 But the answer to the “burning” question of whether we 
should stop research and clinical implementation of RDN based on the results of one 
trial needs a cautious approach.2
The revolutionary therapy of RDN has resulted in significant office BP reduction 
in all previous studies.3-10 The mean office systolic BP reduction across trials is on aver-
age 20-30 mmHg and shows sustainability up to 3 years.3-10 In some patients there is 
delay in the BP response to RDN and there is a gradual drop of BP post-denervation 
suggesting that the adverse vascular and cardiac remodeling characterizing resistant 
hypertension cannot be reversed in all patients in relatively short period of time.10 Thus, 
differences in BP modulation by RDN over time could not be excluded by Symplicity 
HTN 3 that was focused on the 6 months end-point.11
Symplicity HTN-3 is the first to include a sham intervention arm11 mimicking the 
Rheos Pivotal Trial designed to assess the efficacy of baroreflex activation therapy.12 
Patients with the device inactivated exhibited a mean decrease in systolic BP of 9±29 
mmHg that did not differ with the reduction of 16±29 mmHg in the active group 
from month 0 to 6 months (p=0.08).12 However, in this study the 12 month follow-
up revealed greater reduction in BP in both active (25±32 mmHg) and cross-over 
group (25±31 mmHg).12 Due to the lack of studies with placebo groups in resistant 
hypertension the sham-effect should be interpreted with caution. Moreover, controls 
in the randomized Symplicity HTN-2 trial had no systolic BP change but there was no 
placebo provided.6 Pooled data from intentional BP lowering trials reveal that there 
is 12.8 mmHg difference in systolic BP levels from baseline in the placebo group and 
the achieved systolic BP difference between active therapy and placebo is 11.8 mmHg.2 
The lowest prespecified systolic BP deviation from baseline in RDN patients was 15 
mmHg that is close to expected placebo-sham-effect; it reveals the inherent weakness 
of the trial design in terms of assessing the true differential to sham RDN efficacy.2,11
The procedure per se could have an adverse impact on RDN-induced BP changes. 
There is large operator variability and a steep learning curve with the use of the single 
tip ablation catheter which in addition to the small average number of procedures in 
the 87 medical centers involved could result in ineffective ablation of the renal artery.1,2 
Having no marker of RDN success the interventionalist’s experience is needed for 
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maximizing effective ablation.
One of the acknowledged drawbacks of RDN trials is 
the considerable discrepancy between average office BP and 
average 24-h BP at baseline and the marked difference in the 
magnitude of BP reduction during follow up.13 In the series 
of Symplicity, ambulatory BP was performed only in a small 
subset of patients: (12/45 patients in Symplicity HTN-I and 
20/106 patients in Symplicity HTN-II) and BP reduction was 
only 41% and 34% of office BP reduction in the two studies.6,8 
Contrariwise, by antihypertensive drug therapy ambulatory BP 
reduction is at least 65% of the reduction seen in office BP.14 
Similar disparities have also been noted in the EnligHTN I trial 
in which office BP was reduced significantly and substantially 
in the first month (-28/-10 mmHg) and remained at the same 
levels for up to 6 months.9 Ambulatory BP measurement was 
performed in all patients and demonstrated a-10/-5 mmHg 
reduction in average 24-h BP, which also remained the same 
until the 6 month follow-up.9 Recently a larger study spe-
cifically examined the BP response to RDN as measured by 
ambulatory BP monitoring.15 In patients with true treatment 
resistant hypertension (n=303) there was a significant reduc-
tion in 24-h systolic BP (-10/-10/-12 mmHg, p<0.001) and 
diastolic BP (-5/-5/-7 mmHg, p<0.001), at 3, 6 and 12 months, 
respectively.15 There was no effect in pseudo-resistant patients 
(n=43), while office BP was reduced to a similar extent.15 In a 
study including the experience of 10 European expert centers 
revealed a more modest decrease in office systolic/diastolic BP 
after RDN (-17.6/-7.1 mm Hg) that was accompanied by -5.9/-
3.5 mmHg drop in 24-h BP.16 Moreover, although criticizing 
the RDN method, a very recent work comparing RDN versus 
impedance cardiography adjusted-drug treatment revealed 
an ambulatory BP reduction of -10/-7 mmHg in the RDN 
group that could not by any means be considered clinically 
unmeaningful.17
Based on the above, knowing the exact difference of office 
and ambulatory BP in the Symplicity HTN-3 inclusion phase as 
well as the drops of these BP parameters is essential in order 
to assess RDN efficacy. Moreover, due to that reduction of 
24-h hemodynamic load is more closely related to target or-
gan damage and cardiovascular prognosis compared to office 
BP,14 future RDN studies should focus on the reduction of 
ambulatory BP and hard-end points instead of plain office BP.
However, apart from the efficacy BP lowering issues, 
Symplicity HTN-III fulfilled the ethical precept of medicine 
‘primum non nocere’ by successfully meeting the primary 
safety end-point.1 RDN according to all trials is overall a safe 
procedure3-10 and regarding renal function it is preserved even 
in patients with baseline renal failure.18,19 Vascular complica-
tions are rather rare, while renal stenoses are infrequent and 
related to energy delivery in sites of previous atherosclerosis.3-10 
Moreover, the neural cardiovascular reflexes remain intact 
during exercise20 and upright posture21 after RDN.
Importantly, the most promising aspect of this method 
of sympathetic neuromodulation is its pleiotropic nature.22 
Several reports have shown favorable impact of RDN on 
cardiac mass assessed by echocardiography and magnetic 
resonance.23,24 Additionally RDN seems to improve glucose 
status,25,26 arrhythmias,27,28 obstructive sleep apnea syndrome26 
by reducing insulin resistance, end-diastolic left ventricular 
and atrial pressures as well as by causing better natriuresis.22-28 
Most interestingly, in certain models of experimental hyper-
tension not accompanied by excess sympathetic activation, 
RDN causes BP drop not by reducing sympathetic outflow but 
mostly due to left shift of pressure-natriuresis curve.22,29 These 
pathophysiological considerations for fundamental co-impact 
of RDN on sodium balance should be assessed in future clinical 
trials. The use of different catheters and energy modalities (i.e. 
radiofrequency, ultrasound, cryotherapy or combination)3,30-34 
ensuring more complete ablation of renal nerves would per-
haps influence BP, metabolic and cardiovascular parameters 
up to a higher degree.
In this context, we strongly believe that there is an emerg-
ing need to discuss on the appropriate design/methodology 
of randomized trials for the true role of RDN in the therapy 
of hypertension and cardiovascular diseases. The key point is 
that RDN is a method that has substantial pathophysiological 
background with experimental and clinical studies supporting 
its effects.22,34 Finally, the lesson to be learned is that when a 
“negative” trial like Symplicity HTN-3 is published (as it will 
be when you read these lines) one should not only be skeptical 
to RDN but also to the trial itself.
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